skip to main content

Ovarian Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersOvarian CancerSCE Medical Oncology

A patient with FIGO III high-grade ovarian cancer has a partial response to first-line platinum chemotherapy. BRCA testing is negative. Bevacizumab was given throughout induction and was tolerated. Which statement about routine niraparib maintenance under NICE TA1129 is correct?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Niraparib is outside TA1129 after tolerated bevacizumab induction

Option D is correct: TA1129 excludes routine niraparib when bevacizumab was given and tolerated during first-line induction. Option C ignores that restriction. Option B invents a germline-only criterion. Option E is not the appraised combination, and option A wrongly treats partial response as an exclusion.

Reference: NICE TA1129: first-line niraparib maintenance in ovarian cancer. https://www.nice.org.uk/guidance/ta1129/chapter/1-Recommendations